Accuray Incorporated (ARAY)
Automate Your Wheel Strategy on ARAY
With Tiblio's Option Bot, you can configure your own wheel strategy including ARAY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ARAY
- Rev/Share 4.5247
- Book/Share 0.4822
- PB 3.2973
- Debt/Equity 4.3234
- CurrentRatio 1.6392
- ROIC 0.0081
- MktCap 163790670.0
- FreeCF/Share 0.1851
- PFCF 8.6056
- PE 242.9298
- Debt/Assets 0.4426
- DivYield 0
- ROE 0.0143
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Why Is Accuray (ARAY) Up 17% Since Last Earnings Report?
Published: May 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Accuray (ARAY) reported earnings 30 days ago. What's next for the stock?
Read More
Accuray to Participate in the Jefferies Global Healthcare Conference 2025
Published: May 29, 2025 by: PRNewsWire
Sentiment: Neutral
MADISON, Wis. , May 29, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today its participation in the Jefferies Global Healthcare Conference 2025.
Read More
Here's Why You Should Hold Accuray Stock in Your Portfolio for Now
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Positive
ARAY continues to witness strength in its flagship, CyberKnife system, along with robust global performance.
Read More
Accuray Showcases New Long-Term Data¹ on Benefits of 5 Session Radiotherapy Treatment for Men with Prostate Cancer at ESTRO 2025
Published: May 07, 2025 by: PRNewsWire
Sentiment: Neutral
More than 40 Clinical Studies Using Accuray Technology Presented at ESTRO 2025; Company Highlights Innovation and Educational Symposia MADISON, Wis. , May 7, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that new data presented at the European Society for Radiotherapy and Oncology (ESTRO) meeting reinforces the benefits of the company's CyberKnife ® System in the treatment of prostate cancer at multiple stages of the cancer journey.
Read More
ARAY Stock Down Despite Q3 Earnings Beat Estimates, Revenues Up Y/Y
Published: May 01, 2025 by: Zacks Investment Research
Sentiment: Positive
Accuray reports solid fiscal third-quarter results, witnessing growth in Product & Services revenues and reduced operating expenses.
Read More
Accuray Incorporated (ARAY) Q3 2025 Earnings Call Transcript
Published: April 30, 2025 by: Seeking Alpha
Sentiment: Neutral
Accuray Incorporated (NASDAQ:ARAY ) Q3 2025 Earnings Call April 30, 2025 4:30 PM ET Company Participants Jesse Chew - Chief Legal Officer Suzanne Winter - President and Chief Executive Officer Ali Pervaiz - Chief Financial Officer Conference Call Participants Brooks O'Neil - Lake Street Capital Markets Marie Thibault - BTIG Jason Wittes - ROTH Capital Operator Good day and welcome to the Accuray Third Quarter Fiscal 2025 Financial Results Conference Call. [Operator Instructions] Please note this event is being recorded.
Read More
Here's Why You Should Hold Accuray Stock in Your Portfolio for Now
Published: March 05, 2025 by: Zacks Investment Research
Sentiment: Positive
ARAY continues to witness strength in its flagship CyberKnife system, along with robust global performance.
Read More
About Accuray Incorporated (ARAY)
- IPO Date 2007-02-08
- Website https://www.accuray.com
- Industry Medical - Specialties
- CEO Ms. Suzanne Winter M.B.A.
- Employees 987